{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:58:41Z","timestamp":1790531921856,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chemoradiotherapy alone is the standard treatment for locally advanced squamous cell anal carcinoma (SCAC). However, up to 50% of patients will experience recurrence; thus, there is a need for new treatments to improve outcomes. Modified docetaxel, cisplatin and 5-fluorouracil (mDCF) is a treatment option for first-line metastatic SCAC, having shown efficacy in the Epitopes-HPV01 and -02 trials (NCT01845779 and NCT02402842). mDCF treatment also plays a role in the modulation of anti-tumor immunity, suggesting it may be a good combination partner for immunotherapy in patients with SCAC. Anti-programmed death protein-1 (PD-1) immunotherapy has been shown to be effective in metastatic SCAC. We therefore designed the INTERACT-ION study to assess the combination of mDCF with ezabenlimab (BI 754091), an anti-PD-1 antibody, followed by chemoradiotherapy, in patients with Stage III SCAC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>INTERACT-ION is a pivotal, open-label, single-arm phase II study in patients with treatment-na\u00efve Stage III SCAC. Patients will receive induction treatment with mDCF (docetaxel 40 mg\/m<jats:sup>2<\/jats:sup> and cisplatin 40 mg\/m<jats:sup>2<\/jats:sup> on Day 1, 5-fluorouracil 1200 mg\/m<jats:sup>2<\/jats:sup>\/day for 2 days) every 2 weeks for 4 cycles and ezabenlimab (240 mg given intravenously) every 3 weeks for 3 cycles. In the absence of disease progression at 2 months, two additional cycles of mDCF and one additional cycle of ezabenlimab will be administered. Patients with radiological objective response, pathological complete\/near-complete response and biological complete response will then receive an involved-node radiotherapy with intensity-modulated radiation therapy and concurrent chemotherapy, followed by ezabenlimab alone for seven cycles. All other patients will receive standard chemoradiotherapy. The primary endpoint is the clinical complete response rate 10 months after the first cycle of mDCF plus ezabenlimab. Major secondary endpoints are major pathological response and biological complete response after induction treatment. An extensive ancillary biomarker study in tumor tissue and peripheral blood will also be conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The addition of immunotherapy to chemotherapy is an area of active interest in metastatic anal cancer. This pivotal study will evaluate this combination in the locally advanced setting. Ancillary biomarker studies will contribute to the understanding of predictors of response or resistance to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04719988<\/jats:uri>, identifier NCT04719988.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.918499","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T12:33:31Z","timestamp":1661949211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Stefano","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Boustani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Quero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00ebtitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoist","family":"Chibaudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid El","family":"Hajbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Vernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Rebucci-Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Feuersinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Maritaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw276","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz219","article-title":"Recent trends in squamous cell carcinoma of the anus incidence and mortality in the united states, 2001-2015","volume":"112","author":"Deshmukh","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.09.049","article-title":"Anal squamous cell carcinoma: radiation therapy alone must be avoided","volume":"247","author":"Almaazmi","year":"2020","journal-title":"J Surg Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the united states","volume":"31","author":"Nelson","year":"2013","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and hiv status: a systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up()","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12885-020-06841-1","article-title":"Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mdcf) regimen versus mdcf in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25188","article-title":"Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: The intergroup trial (RTOG 98-11)","volume":"116","author":"Ajani","year":"2010","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving Fluorouracil\/Mitomycin versus Fluorouracil\/Cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): A multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1758835920975356","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115 patients from updated data of epitopes-HPV01 and epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.3390\/ijms21186838","article-title":"Anti-telomerase CD4(+) Th1 immunity and monocytic-Myeloid-Derived-Suppressor cells are associated with long-term efficacy achieved by docetaxel, cisplatin, and 5-fluorouracil (DCF) in advanced anal squamous cell carcinoma: Translational study of epitopes-HPV01 and 02 trials","volume":"21","author":"Spehner","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/380079a0","article-title":"Telomerase activation by the E6 gene product of human papillomavirus type 16","volume":"380","author":"Klingelhutz","year":"1996","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1064","article-title":"542P ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours","volume":"32","author":"Patel","year":"2021","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1200\/JCO.2022.40.16_suppl.3508","article-title":"Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.10.002","article-title":"Anal carcinoma - survival and recurrence in a large cohort of patients treated according to Nordic guidelines","volume":"113","author":"Leon","year":"2014","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2021.11.015","article-title":"Radiotherapy of anal canal cancer","volume":"26","author":"Peiffert","year":"2022","journal-title":"Cancer Radiother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2580-z","article-title":"Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide","volume":"135","author":"Campian","year":"2017","journal-title":"J Neurooncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: A systematic review and meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): A Post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.3390\/cancers13153895","article-title":"Present and future research on anal squamous cell carcinoma","volume":"13","author":"Spehner","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.918499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T12:33:34Z","timestamp":1661949214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.918499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.918499"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.918499","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"article-number":"918499"}}